Anthos Therapeutics News and Activities

View the org chart displaying its 20 main executives

Most searched biographies at Anthos Therapeutics

• Bill Meury, Chief Executive Officer
• Ari Brettman, Director
• Scott Beardsley, Director

Popular executive movements at Anthos Therapeutics

• Will Kane, President and Chief Commercial Officer, has left the company  (posted on May 13 2025).
• Venkat Ramanan, Chief Financial Officer, has left the company  (posted on May 13 2025).
• Venkat Ramanan has joined the company as Chief Financial Officer  (posted on November 1 2024).

Click here to view some more movements at Anthos Therapeutics

Create your alert
to follow the executive moves at Anthos Therapeutics.

Anthos Therapeutics has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Anthos Therapeutics

• Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion  - Anthos Therapeutics
• Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with At
• Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - Anthos Therapeutics
• Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer - Anthos Therapeutics
• Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer - Anthos Therapeutics
• New anti-clotting medication reduces bleeding among people with atrial fibrillation
• New anti-clotting medication found to reduce bleeding among people with atrial fibrillation
• View more press releases Close

Social media about Anthos Therapeutics

• Anthos Therapeutics on Wikipedia, Google News & Yahoo Finance
• Anthos Therapeutics on LinkedIn, Twitter & YouTube